BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

01.26.2021

BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

01.25.2021

BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes

01.25.2021

Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.

01.19.2021

BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger

01.13.2021

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01.06.2021

Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger

01.04.2021

UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

12.23.2020

BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease

12.07.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12.04.2020

BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

12.01.2020

BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations

11.13.2020

BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update

11.05.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11.04.2020

BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

10.27.2020

BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases

10.21.2020

Salk Institute and BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease

10.21.2020

BRIDGEBIO PHARMA AND EIDOS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

10.05.2020

BridgeBio Pharma And Affiliate Origin Biosciences Announces FDA Acceptance Of Its New Drug Application For Fosdenopterin For The Treatment Of MoCD Type A

09.29.2020

BridgeBio Pharma and affiliate Origin Biosciences announces FDA acceptance of its new drug application for fosdenopterin for the treatment of MoCD Type A

09.29.2020

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter and Facebook to keep up with all of the latest news.

news archive

icon icon